Enabling access to healthcare for the underserved
Two out of every three Indians die of Non-Communicable Diseases (NCD) such as diabetes, heart disorder and cancer.(1)(2)
The rising epidemic of diabetes is preventing sustainable development in India. Although well-established treatments and prevention options are available, the threat is still increasing at an alarming rate. Unchecked, it will continue to overwhelm healthcare systems, creating spiralling costs and devastating million more lives every year.
Given its pioneering work in development of insulin/insulin pens, knowledge and treatment of NCDs and diabetes. Sanofi is uniquely positioned to work with health systems including authorities and other partners to prevent and treat these diseases.
Goa’s population is facing diabetes-related issues that are growing at an alarming rate. Immediate action is required to curb this menace, so the State does not face repercussions in the foreseeable future. We look forward to partnering Sanofi in battling various non-communicable diseases such as diabetes, cancer and heart disorders, which are collectively known to be responsible for over 70% of all deaths, worldwide*.
Shri Vishwajit Pratapsingh Rane
Hon’ble Minister of State for Health, Craftsmen Training, Women and Child Development, Goa
KiDS (Kids & Diabetes in Schools) Education & engagement amongst children, teachers and parents across 300 schools to help curtail the overall long-term disease burden on the State
KiDS (Kids & Diabetes in Schools) Education & engagement amongst children, teachers and parents across 300 schools to help curtail the overall long-term disease burden on the State
All-India Type 1 diabetes access program for early diagnosis and better Type 1 diabetes management
#EveryLifeIsPrecious
Sanofi’s India Charitable Access Program (INCAP) – part of Sanofi Genzyme’s global humanitarian program – provides free treatment to patients in India afflicted with Rare Diseases like Gaucher, Pompe, Fabry and MPS Type I (aka Lysosomal Storage Disorders)
For patients with Rare diseases, Sanofi is committed to not only develop effective therapies but also ensure that these therapies reach them, regardless of their ability to pay, through our free drug programs. India Charitable Access Program (INCAP) is our free drug program through which we are currently providing free Enzyme Replacement Therapy (ERT) to around 120 patients with any of the four Lysosomal Storage Disorders (LSDs) - Gaucher disease, Pompe disease, Fabry disease and MPS I disease. Our Humanitarian program in India began in 1999, even though the commercial operations of Genzyme started only in 2007. The program is guided by an expert medical committee that remains closely involved in participating patients' care and progress.
Sanofi Genzyme, over the years, has worked closely with multiple stakeholders in capacity building in the field of Genetics and Rare Diseases.
Two of the key organizations that we have partnered with are:
Reference
(1) Source: India: Health of Nation’s States – Indian Council of Medical Research, Public Health Foundation of India, Institute for Health Metrics and Evaluation, Nature Asia
(2) Source: NFHS 2015-16, PHFI ICRM Study 2017
*https://www.who.int/news-room/feature-stories/ten-threats-to-global-health-in-2019